Elritercept (MF anemia)

Current understanding

To be populated as evidence accumulates.

2026-07-16 — An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions: cross-connection with luspatercept: Both are activin receptor ligand traps being developed for JAKi-associated anemia in myelofibrosis — parallel Phase 3 development programs targeting the same clinical niche. (novelty: 3)
2026-06-03 — A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib: Trial-late (randomized placebo-controlled): elritercept add-on vs placebo in MF patients on ruxolitinib with anemia, evaluating anemia response, fatigue, MF symptoms, and physical function — first placebo-controlled late-phase test of a TGF-β/activin ligand trap on a ruxolitinib backbone. (novelty: 3)